AstraZeneca (AZN.US) Relizumab's new indication is proposed for priority review

智通财经2026/10/12 23:11

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

According to Jin Zhi Finance APP, on October 12, the website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration showed that a new indication of AstraZeneca (AZN.US) ravulizumab injection is proposed to be included in priority review, aiming to reduce proteinuria levels in adult patients with primary IgA nephropathy (IgAN). Ravulizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billion USD in 2025 (YOY +20.23%).

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AstraZeneca (AZN.US) Relizumab's new indication is proposed for priority review

You may also like

Crypto prices